104 related articles for article (PubMed ID: 9731502)
21. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
22. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
[TBL] [Abstract][Full Text] [Related]
23. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
[TBL] [Abstract][Full Text] [Related]
24. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
25. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
26. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.
Sharma S; Stolina M; Lin Y; Gardner B; Miller PW; Kronenberg M; Dubinett SM
J Immunol; 1999 Nov; 163(9):5020-8. PubMed ID: 10528207
[TBL] [Abstract][Full Text] [Related]
27. Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice.
Savai R; Schermuly RT; Schneider M; Pullamsetti SS; Grimminger F; Seeger W; Banat GA
J Immunother; 2006; 29(2):175-87. PubMed ID: 16531818
[TBL] [Abstract][Full Text] [Related]
28. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors.
Gladow M; Uckert W; Blankenstein T
Eur J Immunol; 2004 Jul; 34(7):1882-91. PubMed ID: 15214036
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
30. Impaired anti-viral T cell responses due to expression of the Ly49A inhibitory receptor.
Zajac AJ; Vance RE; Held W; Sourdive DJ; Altman JD; Raulet DH; Ahmed R
J Immunol; 1999 Nov; 163(10):5526-34. PubMed ID: 10553080
[TBL] [Abstract][Full Text] [Related]
31. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
32. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
[TBL] [Abstract][Full Text] [Related]
33. TCR vaccines for active immunotherapy of T cell malignancies.
Okada CY; Wong CP; Denney DW; Levy R
J Immunol; 1997 Dec; 159(11):5516-27. PubMed ID: 9548492
[TBL] [Abstract][Full Text] [Related]
34. [Effect of cytotoxic lymphocytes obtained by in vitro immunization with syngeneic lymphoma cells on pluripotent hemopoietic cells].
Voĭtenok NN; Mitskevich PB; Murzenok PP
Biull Eksp Biol Med; 1985 May; 99(5):604-6. PubMed ID: 3873966
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.
Sarma S; Guo Y; Guilloux Y; Lee C; Bai XF; Liu Y
J Exp Med; 1999 Mar; 189(5):811-20. PubMed ID: 10049945
[TBL] [Abstract][Full Text] [Related]
36. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
von Hoegen P; Heicappell R; Griesbach A; Altevogt P; Schirrmacher V
Invasion Metastasis; 1989; 9(2):117-33. PubMed ID: 2785093
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells.
Stärck L; Popp K; Pircher H; Uckert W
J Immunol; 2014 Jan; 192(1):206-13. PubMed ID: 24293634
[TBL] [Abstract][Full Text] [Related]
38. 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
Matthews KE; Hermans IF; Roberts JM; Ching LM; Ronchese F
Immunol Cell Biol; 2006 Aug; 84(4):383-9. PubMed ID: 16834573
[TBL] [Abstract][Full Text] [Related]
39. An examination of tumor antigen loss in spontaneous metastases.
Dennis JW; Donaghue TP; Kerbel RS
Invasion Metastasis; 1981; 1(2):111-25. PubMed ID: 6985358
[TBL] [Abstract][Full Text] [Related]
40. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice.
Otahal P; Schell TD; Hutchinson SC; Knowles BB; Tevethia SS
J Immunol; 2006 Sep; 177(5):3089-99. PubMed ID: 16920946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
